Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke University, Duke Cancer Institute, Exelixis (United States), Massachusetts General Hospital, University of Chicago Medical Center, Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Washington University in St. Louis, UCSF Helen Diller Family Comprehensive Cancer Center, University of Kansas, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2791429907